Nivolumab plus ipilimumab for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC): Additional results from the randomized phase 2 CheckMate 650 trial.

被引：0

作者：

Sharma, Padmanee

Krainer, Michael

Saad, Fred

Castellano, Daniel

Bedke, Jens

Kwiatkowski, Mariusz

Patnaik, Akash

Procopio, Giuseppe

Wiechno, Pawel

Kochuparambil, Samith Thomas

Thomas, Christian

Arija, Jose Angel Arranz

McCune, Steven L.

Hansen, Steinbjorn

Daugaard, Gedske

Amin, Neha P.

Wang, Yumeng

David, Justin M.

Pachynski, Russell Kent

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[2] Med Univ Vienna, Vienna, Austria

[3] Univ Montreal Hosp Ctr, Montreal, PQ, Canada

[4] Hosp Univ 12 Octubre, Madrid, Spain

[5] Eberhard Karls Univ Tubingen, Tubingen, Germany

[6] Szpital Wojewodzki Mikolaja Kopernika w Koszalini, Oddzial Dzienny Chemioterapii, Koszalin, Poland

[7] Univ Chicago Med, Chicago, IL USA

[8] Ist Nazl Tumori Milano, Milan, Italy

[9] Maria Sklodowska Curie Mem Canc Ctr, Warsaw, Poland

[10] Minnesota Oncol, Minneapolis, MN USA

[11] Natl Ctr Tumor Dis, Heidelberg, Germany

[12] Hosp Gen Univ Gregorio Maranon, Madrid, Spain

[13] Northwest Georgia Oncol Ctr, Marietta, GA USA

[14] Odense Univ Hosp, Odense, Denmark

[15] Rigshosp, Univ Copenhagen Hosp, Copenhagen, Denmark

[16] Bristol Myers Squibb, Princeton, NJ USA

[17] Washington Univ, Sch Med, St Louis, MO USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：1

共 50 条

[41] ABIRATERONE AND ENZALUTAMIDE FOR THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) POST CHEMOTHERAPY: AN INDIRECT COMPARISON AND BUDGET IMPACT ANALYSIS
Li, T.
Thompson, M.
Todd, M.
Yu, M.
Kheoh, T.
Saadi, R.
VALUE IN HEALTH, 2013, 16 (07) : A394 - A394
[42] Survival benefit from first docetaxel treatment for cabazitaxel plus prednisone compared with mitoxantrone plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in the TROPIC trial.
Sartor, A. O.
Oudard, S.
Ozguroglu, M.
Hansen, S.
Machiels, J. H.
Shen, L.
De Bono, J. S.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[43] Quality of life (QOL) for the treatment sequence of abiraterone acetate plus prednisone (AAP) followed by enzalutamide (ENZ) versus the opposite sequence for metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized clinical trial.
Khalaf, Daniel J.
Sunderland, Katherine
Eigl, Bernhard J.
Finch, Daygen L.
Oja, Conrad D.
Vergidis, Joanna
Zulfiqar, Muhammad
Kollmannsberger, Christian K.
Gleave, Martin
Chi, Kim N.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[44] Tolerability of abiraterone (abi) combined with olaparib (ola) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Further results from the phase III PROpel trial.
Thiery-Vuillemin, Antoine
Saad, Fred
Armstrong, Andrew J.
Oya, Mototsugu
Vianna, Karina Costa Maia
Ozguroglu, Mustafa
Gedye, Craig
Buchschacher, Gary L.
Lee, Ji Youl
Emmenegger, Urban
Navratil, Jiri
Virizuela, Juan Antonio
Salazar, Anibal
Maillet, Denis
Uemura, Hiroji
Kim, Jeri
Lukacs, Edit
Barker, Laura
Degboe, Arnold N.
Clarke, Noel W.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[45] Phase-III Study in Patients with metastatic castration-resistant Prostate Cancer (mCRPC) A randomized, double-blind Study of Nivolumab or Placebo in Combination with Docetaxel in Men with metastatic castration-resistant Prostate Cancer (CheckMate-7DX) - Study AP 118/21 of the AUO
Rexer, H.
Boegemann, M.
Hammerer, P.
UROLOGE, 2022, 61 (03): : 345 - 346
[46] ENCORE: A phase 2 trial of enfortumab vedotin (EV) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Swami, Umang
Faust, Caitlin
Leonhart, Samuel
Haaland, Benjamin
Jones, Kristen
Li, Haoran
Sahu, Kamal Kant Kant
Thomas, Vinay Mathew
Phunrab, Tenzin Kunsang
Batten, Julia
Maxwell, Lindsay
Lloyd, Jennifer
Kohli, Manish
Gupta, Sumati
Thorne, Kelli
Maughan, Benjamin L.
Agarwal, Neeraj
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[47] Phase II study of cabazitaxel (CAB) plus enzalutamide (ENZ) in metastatic castration-resistant prostate cancer (mCRPC)
Graff, Julie Nicole
Cheng, Heather H.
Vuky, Jacqueline
Alumkal, Joshi J.
Kreitner, Dustin
Petreaca, Delia
Grivas, Petros
Schweizer, Michael Thomas
Higano, Celestia S.
Chen, Yiyi
Yu, Evan Y.
Beer, Tomasz M.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[48] BRCAAWAY: A randomized phase 2 trial of abiraterone, olaparib, or abiraterone plus olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) with DNA repair defects.
Hussain, Maha H. A.
Kocherginsky, Masha
Agarwal, Neeraj
Zhang, Jingsong
Adra, Nabil
Paller, Channing Judith
Picus, Joel
Reichert, Zachery R.
Szmulewitz, Russell Zelig
Tagawa, Scott T.
Whang, Young E.
Dreicer, Robert
Kuzel, Timothy
Bazzi, Latifa
Gerke, Travis A.
Daignault-Newton, Stephanie
Chinnaiyan, Arul
Antonarakis, Emmanuel S.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[49] Real-life data of abiraterone acetate and enzalutamide treatment in post-chemotherapy metastatic castration-resistant prostate cancer in Poland
Sigorski, Dawid
Wilk, Michal
Gawlik-Urban, Angelika
Salek-Zan, Agata
Kiszka, Joanna
Malik, Mateusz
Czerko, Katarzyna
Kuc, Kamil
Szczylik, Cezary
Kubiatowski, Tomasz
Cybulska-Stopa, Bozena
Filipczyk-Cisarz, Emilia
Bodnar, Lubomir
Skoneczna, Iwona
FRONTIERS IN ONCOLOGY, 2023, 13
[50] Development and validation of a prognostic model for overall survival in chemotherapy-naive men with metastatic castration-resistant prostate cancer (mCRPC) from the phase III PREVAIL clinical trial.
Armstrong, Andrew J.
Lin, Ping
Higano, Celestia S.
Sternberg, Cora N.
Sonpavde, Guru
Tombal, Bertrand F.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)

← 1 2 3 4 5 →